Skip to content

Possibilities of Use MRI-Guided Laser Interstitial Thermal Therapy in Medically Intractable Tremor

Possibilities of Use Magnetic Resonance Imaging (MRI)-Guided Laser Interstitial Thermal Therapy (LITT) in Treatment of Medically Intractable Tremor

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06799923
Acronym
PossibiLITT
Enrollment
15
Registered
2025-01-29
Start date
2024-08-01
Completion date
2026-04-30
Last updated
2025-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential Tremor, Laser Interstitial Thermal Therapy, Movement Disorders, MRI, Parkinson Disease

Keywords

laser interstitial thermal therapy, Parkinson Disease, Essential Tremor, Movement Disorders, MRI

Brief summary

Medically intractable tremors are a common difficult clinical situation. Deep brain stimulation decreases Parkinson's disease tremor and essential tremor, but not all patients are candidates from a diagnostic, medical, or social standpoint, prompting the need for alternative surgical strategies. Less invasive lesional brain surgery (thalamotomy) procedures by radio-surgery or MRI-guided focused ultrasound have emerged and have proven to be effective in these third-line indications. Recently, a new technology has emerged allowing the performance of minimally invasive lesion surgeries by MRI-Guided Laser Interstitial Thermal Therapy (MRIg-LITT). MRIg-LITT has been shown to be effective and safe in management of epilepsies and brain tumors. However, no study has evaluated MRIg-LITT for performing thalamotomy in medically intractable tremor.In a pilot study, the investigators propose to evaluate the effect and safety of unilateral thalamotomy by MRIg-LITT in the management of medically intractable tremor of parkinsonian or essential origin.

Interventions

PROCEDURElaser electrode

A laser electrode is implanted surgically in the ventral and inteermediary nucleus of the thalamus (VIM).

Sponsors

University Hospital, Rouen
CollaboratorOTHER
University Hospital, Caen
CollaboratorOTHER
Central Hospital Saint Quentin
CollaboratorOTHER_GOV
Centre Hospitalier Universitaire, Amiens
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients 18 years age or older with Parkinson's disease or essential tremor and tremor resistant to medical therapy with a contraindication to deep brain stimulation or refusal deep brain stimulation

Exclusion criteria

* Contraindication to MRI * Contraindication to general anesthesia * Patient unable to give their free and informed consent because of cognitive or psychiatric disorders * Brain anatomical abnormalities not allowing intervention * Adults protected (guardianship, curators) or deprived of liberty.

Design outcomes

Primary

MeasureTime frameDescription
Variation of total body weight from baselineat 72 hoursTo assess the impact of UF prescription guided by the ECW/TBWat ratio on weight loss, a comparison of TBW (∆TBW) between the two groups will be conducted. The ∆TBW is the difference between the initial TBW at H0 and the TBW at H72.

Secondary

MeasureTime frameDescription
cumulative fluid balanceat 72 hoursCumulative fluid balance is the difference between fluids administered (intravenous fluids, blood products, enteral nutrition, replacement fluid from RRT) and fluid loss (weight loss from RRT, urine output, blood loss, enteral loss, and losses through drains). It is calculated using the cumulative net UF from RRT and the hospital software (DianeRéa, Bowmedical, version 4.8.11.22887) over the period from H0 to H72.

Countries

France

Contacts

Primary ContactMichel LEFRANC, Pr
lefranc.michel@chu-amiens.fr0322088950

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026